ClassID:

109613

C12N2710/10021 - CPC Classification

Classification description:

dsDNA viruses; Details; Adenoviridae Viruses as such, e.g. new isolates, mutants or their genomic sequences

Recent Application in this class:
#1
20260102445
2026-04-16

ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE

#2
20250327037
2025-10-23

TUMOR-SELECTIVE E1A AND E1B MUTANTS

#3
20250312429
2025-10-09

ANTI-GUCY2C VACCINES AND VACCINATION

#4
20250304959
2025-10-02

PROGRAMMABLE RECRUITMENT OF TRANSCRIPTION FACTORS TO ENDOGENOUS GENES

#5
20250302897
2025-10-02

METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY COMBINATION THERAPY

#6
20250249055
2025-08-07

ADENOVIRUS CONSTRUCTS AND METHODS OF USE

#7
20250235493
2025-07-24

Recombinant Viral Genomes and Related Compositions and Methods

#8
20250171745
2025-05-29

ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S)

#9
20250027056
2025-01-23

Adeno-Associated-Virus Rep Sequences, Vectors and Viruses

#10
20240301362
2024-09-12

ADENOVIRAL SEROTYPE 35 HELPER VECTORS

#11
20240191255
2024-06-13

Adenoviral Vectors

#12
20240181078
2024-06-06

Simian Adenovirus and Hybrid Adenoviral Vectors

#13
20240016914
2024-01-18

Targeted neoepitope vectors and methods therefor

#14
20230405085
2023-12-21

PREVENTION AND/OR TREATMENT OF HEARING LOSS OR IMPAIRMENT

#15
20230272349
2023-08-31

Tumor-selective E1a and E1b mutants

#16
20230220355
2023-07-13

RECOMBINANT ADENOVIRUS GENOME HAVING A SYNTHETIC TRANSCRIPTIONAL UNIT AND TWO STEP TRANSCRIPTIONAL REGULATION AND AMPLIFICATION

#17
20230052537
2023-02-16

Methods of treating solid or lymphatic tumors by combination therapy

#18
20230001014
2023-01-05

DETARGETED ADENOVIRUS VARIANTS AND RELATED METHODS

#19
20220204993
2022-06-30

Compositions And Methods For Viral Delivery Of Neoepitopes And Uses Thereof

#20
20220118080
2022-04-21

Modified viruses

#21
20220096577
2022-03-31

ONCOLYTIC ADENOVIRUS COMPOSITIONS

#22
20220054563
2022-02-24

DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES

#23
20210403564
2021-12-30

Oncolytic virus expressing PD-1 binding protein and application of oncolytic virus

#24
20210301264
2021-09-30

ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S)

#25
20210269827
2021-09-02

MODIFIED SEROTYPE 28 ADENOVIRAL VECTORS

#26
20210268405
2021-09-02

METHOD FOR PRODUCING RECOMBINANT ADENOVIRUS

#27
20210171917
2021-06-10

Tumor-selective E1A and E1B mutants

#28
20210128653
2021-05-06

Replication-enhanced oncolytic adenoviruses

#29
20200392188
2020-12-17

Recombinant human replication-deficient adenovirus comprising a modified nucleic acid encoding the Marburg virus envelope glycoprotein

#30
20200360533
2020-11-19

Simian adenovirus and hybrid adenoviral vectors

#31
20200353039
2020-11-12

Prevention and/or treatment of hearing loss or impairment

#32
20200291432
2020-09-17

Compositions and methods for viral delivery of neoepitopes and uses thereof

#33
20200172873
2020-06-04

Cell line for producing adenovirus and method of preparing the same

#34
20200155625
2020-05-21

ANTI-ANGIOGENIC ADENOVIRUS

#35
20200147204
2020-05-14

Modified viruses

#36
20200054730
2020-02-20

Targeted neoepitope vectors and methods therefor

#37
20190388487
2019-12-26

Detargeted adenovirus variants and related methods

#38
20190382793
2019-12-19

Adenoviral vectors

#39
20190292525
2019-09-26

Adeno-associated-virus Rep sequences, vectors and viruses

#40
20190183946
2019-06-20

ONCOLYTIC ADENOVIRUSES FOR CANCER TREATMENT

#41
20190153472
2019-05-23

Methods and compositions for performing continuous directed evolution

#42
20190136204
2019-05-09

Tumor-selective E1a and E1b mutants

#43
20190093085
2019-03-28

ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S)

#44
20190070233
2019-03-07

Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor

#45
20180363005
2018-12-20

Compositions and methods for viral delivery of neoepitopes and uses thereof

#46
20180244750
2018-08-30

METHODS FOR TREATMENT OF CANCER

#47
20180179554
2018-06-28

Human type 55 replication defective adenovirus vector, method for preparing same and uses thereof

#48
20180100164
2018-04-12

Modified serotype 28 adenoviral vectors

#49
20180099015
2018-04-12

Detargeted adenovirus variants and related methods

#50
20180055908
2018-03-01

Prevention and/or treatment of hearing loss or impairment

#51
20180000966
2018-01-04

Simian adenovirus and hybrid adenoviral vectors

#52
20170314018
2017-11-02

LncRNA and oncolytic adenovirus, and application thereof

#53
20170313990
2017-11-02

A PROCESS FOR THE PRODUCTION OF ADENOVIRUS

#54
20170080036
2017-03-23

PPSA and Pspa polymer-virus complex and pharmaceutical compositions comprising the same

#55
20170028017
2017-02-02

Microcin and uses thereof

#56
20160354420
2016-12-08

Oncolytic adenoviruses for cancer treatment

#57
20160333323
2016-11-17

Conditionally replicating adenovirus

#58
20160289645
2016-10-06

Adenovirus Expressing Immune Cell Stimulatory Receptor Agonist(s)

#59
20160271192
2016-09-22

Subfamily E simian adenoviruses A1321, A1325, A1295, A1309, A1316 and A1322 and uses thereof

#60
20160264629
2016-09-15

Adenovirus isolated from titi monkeys

#61
20160120922
2016-05-05

Dosing regime and formulations for type B adenovirus

#62
20160090574
2016-03-31

A PROCESS FOR THE PRODUCTION OF ADENOVIRUS

#63
20160082100
2016-03-24

RECOMBINANT SEROTYPE 5 (Ad5) ADENOVIRAL VECTORS

#64
20160017294
2016-01-21

TUMOR-SELECTIVE E1A AND E1B MUTANTS

#65
20160002607
2016-01-07

Adeno-associated-virus Rep sequences, vectors and viruses

#66
20150374766
2015-12-31

Oncolytic adenovirus compositions

#67
20150359871
2015-12-17

Immunogenic compositions comprising silicified virus and methods of use

#68
20150337270
2015-11-26

Recombinant adenovirus with increased safety and anticancer activities, and use thereof

#69
20150232811
2015-08-20

Recombinant serotype 5 (Ad5) adenoviral vectors

#70
20150202324
2015-07-23

ADENOVIRAL VECTORS AND METHODS AND USES RELATED THERETO

#71
20150167018
2015-06-18

Modified serotype 28 adenoviral vectors

#72
20150164983
2015-06-18

Microcin and uses thereof

#73
20150071881
2015-03-12

Oncolytic Adenoviruses for Cancer Treatment

#74
20150044766
2015-02-12

Simian adenovirus and hybrid adenoviral vectors

#75
20150037874
2015-02-05

Chimeric adenoviruses for use in cancer treatment

#76
20140356328
2014-12-04

Subfamily E simian adenoviruses A1321, A1325, A1295, A1309, A1316 and A1322 and uses thereof

#77
20130230902
2013-09-05

Chimeric adenoviruses for use in cancer treatment

#78
20130209409
2013-08-15

Chimeric adenoviruses for use in cancer treatment

#79
20130004461
2013-01-03

Subfamily E simian adenoviruses A1321, A1325, A1295, A1309, A1316 and A1322 and uses thereof

#80
20120231524
2012-09-13

Chimeric adenoviruses for use in cancer treatment

#81
20110318311
2011-12-29

Tumor selective E1a and E1b mutants

#82
20100222234
2010-09-02

Malaria antigen screening method

#83
20100166799
2010-07-01

Adenoviral vectors and methods and uses related thereto

#84
20090311219
2009-12-17

Oncolytic Adenoviruses for Cancer Treatment

#85
20090227000
2009-09-10

Chimeric adenoviruses for use in cancer treatment

#86
20050265973
2005-12-01

Chimeric adenoviruses for use in cancer treatment